Indian firms fear US generic user fee would raise the cost of business
This article was originally published in Scrip
Executive Summary
The Indian generic industry has reacted with measured optimism to the recent US FDA-industry agreement on generic drug user fees (GDUF), with some experts arguing that there are currently more questions than answers on the proposed fee-based programme's workability.